Latest news with #HELM
TECHx
12 hours ago
- Health
- TECHx
Abu Dhabi, Abbott Partner to Boost Local Pharma Sector
Home » Smart Sectors » Healthcare » Abu Dhabi, Abbott Partner to Boost Local Pharma Sector The Department of Health, Abu Dhabi (DoH), the healthcare sector regulator in Abu Dhabi, announced a strategic partnership with global healthcare leader Abbott. The agreement was signed during the BIO International Convention held in Boston, USA. The partnership aims to localise pharmaceutical manufacturing in Abu Dhabi. It also focuses on advancing digital health solutions across the emirate. Officials revealed that the collaboration builds on Abu Dhabi's advanced life sciences infrastructure. This move supports the emirate's goal to reduce dependency on imports and strengthen supply chain resilience. It further reflects Abu Dhabi's commitment to fostering a self-sufficient and sustainable healthcare ecosystem. Dr. Noura Al Ghaithi, Undersecretary of DoH, stated that the partnership follows the recent launch of the Health, Endurance, Longevity and Medicine (HELM) Cluster in Abu Dhabi. She added that the emirate is equipped with an integrated infrastructure to support local manufacturing and R&D. She said the agreement would position Abu Dhabi as a regional healthcare hub and leader in life sciences. According to her, aligning DoH's strategic vision with Abbott's global expertise will accelerate the delivery of innovative healthcare products and solutions. The collaboration is built around four key pillars: Localising Abbott's pharmaceutical portfolio and developing biosimilars. Advancing digital transformation through electronic patient information leaflets. Launching education programs to strengthen the healthcare workforce. Supporting regulatory alignment and joint R&D initiatives. Mazen Bachir, Regional Director for Abbott's established pharmaceuticals business in the Gulf, Emerging Markets and Levant, reported that this partnership will enhance healthcare resilience and innovation in Abu Dhabi. He highlighted Abbott's ongoing commitment to the UAE's healthcare system. He noted that the partnership will also include digitising life sciences product information and launching training initiatives to build local capabilities. In addition, both parties will explore opportunities for joint research and development. DoH also reported that a high-level delegation has embarked on a strategic mission to the United States from 15 to 21 June 2025. The delegation will conduct over 20 meetings with public and private sector leaders. These meetings aim to promote knowledge exchange, attract investments, and sign new agreements that accelerate advanced health solutions. Representing Abu Dhabi's innovation ecosystem, the delegation includes: Abu Dhabi Investment Office, Mubadala BIO, M42, Masdar City, KEZAD, and PureHealth. Etihad Cargo, New York University Abu Dhabi, Khalifa University, startAD, and Mohamed bin Zayed University of Artificial Intelligence (MBZUAI). This announcement highlights Abu Dhabi's global ambitions in life sciences and healthcare innovation.
Zawya
6 days ago
- Health
- Zawya
Abu Dhabi reinforces global leadership in healthcare innovation with high-level U.S. visit
Abu Dhabi, United Arab Emirates – A high-level delegation led by the Department of Health – Abu Dhabi (DoH), is set to embark on a strategic mission to the United States from June 14 to 21, 2025. The visit reaffirms Abu Dhabi's global leadership in healthcare innovation and reflects its broader vision for healthcare transformation—driven by innovation, investment, and a deep commitment to global collaboration. The delegation will visit key U.S. cities including Boston, Washington D.C., and Philadelphia, in parallel with Abu Dhabi's participation at BIO International Convention 2025, one of the world's foremost biotechnology events. The visit will spotlight the Emirate's achievements in AI, digital health, genomics, and clinical research and showcase Abu Dhabi's Health, Endurance, Longevity and Medicine (HELM) Life Science Cluster, while promoting long-term strategic partnerships with government entities, research institutions, and global innovators. H.E. Dr. Noura Khamis Al Ghaithi, Undersecretary of the Department of Health – Abu Dhabi, stated: 'This mission reflects our commitment to shaping the future of health through collaboration, innovation, and shared purpose. Our vision is to build a health system that predicts, prevents, acts to restore, and acts to cure, therefore ensuring better outcomes for our communities and beyond. This can only be achieved through meaningful partnerships and a shared ambition to improve lives. We are proud to join our partners in the United States to explore new opportunities that advance healthcare, both in the UAE and globally.' The delegation will conduct over 20 strategic meetings and visits with public and private sector leaders across the U.S., aimed at knowledge exchange, investment opportunities, and the signing of new agreements that accelerate the adoption of advanced health solutions. Representing Abu Dhabi's innovation ecosystem, the delegation includes key stakeholders such as the Abu Dhabi Investment Office, Mubadala BIO, M42, Masdar City, KEZAD, PureHealth, and Etihad Cargo. Abu Dhabi continues to lead the region in genomics through the Emirati Genome Programme, which has successfully sequenced over 800,000 samples, creating one of the most advanced national genomic databases. The Emirate is also home to more than 90 licensed research centers and 30+ ongoing clinical trials in areas such as oncology, rare diseases, and chronic conditions. Advanced data platforms such as Malaffi, which securely store over 5 million patient records—enable AI-powered insights and real-world evidence, while national initiatives like the Golden Visa program are cultivating a global workforce and have granted over 2,000 long-term visas for researchers and healthcare professionals from around the world. About the Department of Health – Abu Dhabi (DoH): The Department of Health – Abu Dhabi is the regulative body of the healthcare sector in the Emirate of Abu Dhabi. Committed to ensuring excellence in healthcare, DoH monitors the health status of the population while shaping the regulatory framework for the health system. This includes inspecting against regulations, enforcing standards and encouraging the adoption of world-class best practices and performance targets by all healthcare providers in the Emirate. Abu Dhabi remains dedicated to shaping the future of healthcare by establishing an intelligent and sustainable ecosystem that prioritises health, longevity and quality of life for all community members. Leveraging state-of-the-art infrastructure and cutting-edge capabilities, DoH continues to develop and implement initiatives and programmes in line with its strategic focus areas, Healthy Population, Best-in-Class Care and Resilience and Innovation. These efforts reflect DoH's unwavering commitment to predicting, preventing and personalising healthcare for every individual. For further information on DOH, visit and follow on X, Instagram, Facebook, LinkedIn and YouTube. For media inquiries, please contact: Mariam Al Marzooqi, msalmarzooqi@
Al Bawaba
6 days ago
- Health
- Al Bawaba
Abu Dhabi Reinforces Global Leadership in Healthcare Innovation with High-Level U.S. Visit
A high-level delegation led by the Department of Health – Abu Dhabi (DoH), is set to embark on a strategic mission to the United States from June 14 to 21, 2025. The visit reaffirms Abu Dhabi's global leadership in healthcare innovation and reflects its broader vision for healthcare transformation—driven by innovation, investment, and a deep commitment to global delegation will visit key U.S. cities including Boston, Washington D.C., and Philadelphia, in parallel with Abu Dhabi's participation at BIO International Convention 2025, one of the world's foremost biotechnology visit will spotlight the Emirate's achievements in AI, digital health, genomics, and clinical research and showcase Abu Dhabi's Health, Endurance, Longevity and Medicine (HELM) Life Science Cluster, while promoting long-term strategic partnerships with government entities, research institutions, and global innovators.H.E. Dr. Noura Khamis Al Ghaithi, Undersecretary of the Department of Health – Abu Dhabi, stated: 'This mission reflects our commitment to shaping the future of health through collaboration, innovation, and shared purpose. Our vision is to build a health system that predicts, prevents, acts to restore, and acts to cure, therefore ensuring better outcomes for our communities and beyond. This can only be achieved through meaningful partnerships and a shared ambition to improve lives. We are proud to join our partners in the United States to explore new opportunities that advance healthcare, both in the UAE and globally.'The delegation will conduct over 20 strategic meetings and visits with public and private sector leaders across the U.S., aimed at knowledge exchange, investment opportunities, and the signing of new agreements that accelerate the adoption of advanced health Abu Dhabi's innovation ecosystem, the delegation includes key stakeholders such as the Abu Dhabi Investment Office, Mubadala BIO, M42, Masdar City, KEZAD, PureHealth, and Etihad Dhabi continues to lead the region in genomics through the Emirati Genome Programme, which has successfully sequenced over 800,000 samples, creating one of the most advanced national genomic databases. The Emirate is also home to more than 90 licensed research centers and 30+ ongoing clinical trials in areas such as oncology, rare diseases, and chronic conditions. Advanced data platforms such as Malaffi, which securely store over 5 million patient records—enable AI-powered insights and real-world evidence, while national initiatives like the Golden Visa program are cultivating a global workforce and have granted over 2,000 long-term visas for researchers and healthcare professionals from around the world.
Arabian Business
09-05-2025
- Business
- Arabian Business
Abu Dhabi Investment Office expands San Francisco operation as it targets $25.3tn healthcare market
The Abu Dhabi Investment Office (ADIO) has announced plans to expand operations of its office in San Francisco to support the global expansion of Abu Dhabi's economic clusters. At an epicentre of health tech, biotech, and venture capital, the expansion of the San Francisco office will promote Abu Dhabi's fast-track clinical validation and regulatory pathways to serve as a launchpad for global innovation in healthcare, as well as other priority sectors. The Abu Dhabi's Health, Endurance, Longevity and Medicine cluster (HELM), launched in April 2025 by the Abu Dhabi Department of Economic Development (ADDED) and Abu Dhabi Investment Office (ADIO) in partnership with the Department of Health – Abu Dhabi, is projected to contribute $25.6bn to Abu Dhabi's GDP, unlock 30,000 new jobs, and attract $11.5bn in investment by 2045. Abu Dhabi Investment Office The Cluster, tapping growth opportunities in the global healthcare market, which is projected to reach $25.3tn by 2045, will be a key area of focus for the San Francisco office. One of the largest global health innovation initiatives of its kind, HELM leverages Abu Dhabi's strengths in genomics, population health intelligence, AI in healthcare and regulatory agility. ADIO office will enable US-based startups and scale-ups to join other leading US healthcare firms, such as Insilico Medicine and Innovaccer, in expanding to Abu Dhabi. The announcement was made as part of a high-level delegation visit to San Francisco, led by Mansoor Ibrahim Al Mansoori, Chairman of the Department of Health – Abu Dhabi, to strengthen strategic partnerships and hold meetings with decision-makers, entrepreneurs, and representatives of leading institutions in the health technology and innovation sector in the region. Ahmed Jasim Al Zaabi, Chairman of the Abu Dhabi Department of Economic Development (ADDED), said: 'ADIO's office in San Francisco is more than a presence, it's a platform for investment matching, market entry, and long-term growth. 'By expanding our operations in San Francisco, we're not only opening new doors to Abu Dhabi's business ecosystem, we're building two-way bridges for capital, innovation, and impact across multiple innovation-driven sectors.' Mansoor Ibrahim Al Mansoori, Chairman of the Department of Health – Abu Dhabi, said: 'The future of health cannot be built in isolation; it must be co-created. The expansion of ADIO's office in San Francisco will give health innovators, and entrepreneurs the opportunity to build, test, and scale solutions with Abu Dhabi, for the world. 'As a Living Lab for real-world health innovation, backed by agile, innovation focused regulations, capital and infrastructure, we offer a platform where global ideas can scale and create impact.' Announced during Abu Dhabi Global Health Week 2025, the HELM cluster serves as a launchpad for health and life sciences companies seeking to tap into strategic capital with partners in Abu Dhabi, fast-track market validation through Abu Dhabi's digitally integrated clinical trial and regulatory infrastructure, simultaneously access and expand across two high-value markets—the US and the Middle East, collaborate with leading UAE-based research institutions and healthcare providers and scale globally with bespoke advisory and partnership support.
Zawya
09-05-2025
- Business
- Zawya
Abu Dhabi Investment Office to expand San Francisco office to attract further US investment
ABU DHABI - The Abu Dhabi Investment Office (ADIO) has announced plans to expand operations of its office in San Francisco to support the global expansion of Abu Dhabi's economic clusters. At an epicentre of health tech, biotech, and venture capital, the expansion of the San Francisco office will promote Abu Dhabi's fast-track clinical validation and regulatory pathways to serve as a launchpad for global innovation in healthcare, as well as other priority sectors. The Abu Dhabi's Health, Endurance, Longevity and Medicine cluster (HELM), launched in April 2025 by the Abu Dhabi Department of Economic Development (ADDED) and Abu Dhabi Investment Office (ADIO) in partnership with the Department of Health – Abu Dhabi, is projected to contribute US$25.6 billion to Abu Dhabi's GDP, unlock 30,000 new jobs, and attract US$11.5 billion in investment by 2045. The Cluster, tapping growth opportunities in the global healthcare market, which is projected to reach US$25.3 trillion by 2045, will be a key area of focus for the San Francisco office. One of the largest global health innovation initiatives of its kind, HELM leverages Abu Dhabi's strengths in genomics, population health intelligence, AI in healthcare and regulatory agility. ADIO office will enable US-based startups and scale-ups to join other leading US healthcare firms, such as Insilico Medicine and Innovaccer, in expanding to Abu Dhabi. The announcement was made as part of a high-level delegation visit to San Francisco, led by Mansoor Ibrahim Al Mansoori, Chairman of the Department of Health – Abu Dhabi, to strengthen strategic partnerships and hold meetings with decision-makers, entrepreneurs, and representatives of leading institutions in the health technology and innovation sector in the region. Ahmed Jasim Al Zaabi, Chairman of the Abu Dhabi Department of Economic Development (ADDED), said, 'ADIO's office in San Francisco is more than a presence, it's a platform for investment matching, market entry, and long-term growth. By expanding our operations in San Francisco, we're not only opening new doors to Abu Dhabi's business ecosystem, we're building two-way bridges for capital, innovation, and impact across multiple innovation-driven sectors.' Mansoor Ibrahim Al Mansoori, Chairman of the Department of Health – Abu Dhabi, said, 'The future of health cannot be built in isolation; it must be co-created. The expansion of ADIO's office in San Francisco will give health innovators, and entrepreneurs the opportunity to build, test, and scale solutions with Abu Dhabi, for the world. As a Living Lab for real-world health innovation, backed by agile, innovation focused regulations, capital and infrastructure, we offer a platform where global ideas can scale and create impact.' Announced during Abu Dhabi Global Health Week 2025, the HELM cluster serves as a launchpad for health and life sciences companies seeking to tap into strategic capital with partners in Abu Dhabi, fast-track market validation through Abu Dhabi's digitally integrated clinical trial and regulatory infrastructure, simultaneously access and expand across two high-value markets—the US and the Middle East, collaborate with leading UAE-based research institutions and healthcare providers and scale globally with bespoke advisory and partnership support.
